奎寧定鹽酸鹽
| 中文名称 | 奎寧定鹽酸鹽 |
|---|---|
| 中文同义词 | 奎寧定鹽酸鹽;奎尼丁盐酸盐;奎尼丁单盐酸盐一水合物;奎尼丁 盐酸盐 一水合物;盐酸奎尼丁一水合物;奎尼丁盐酸盐一水合物,10 MM DMSO 溶液;(S)-(6-甲氧基喹啉-4-基)((1S,2R,4S,5R)-5-乙烯基奎宁环-2-基)甲醇 盐酸盐 水合物 |
| 英文名称 | QUINIDINE HYDROCHLORIDE |
| 英文同义词 | Quinidine hydrochloride monohydrate technical grade;QUINIDINE HYDROCHLORIDE;QUINIDINE HYDROCHLORIDE MONOHYDRATE;QUINIDINE HYDROCHLORIDE MONOHYDRATE CRYSTALLINE;Quinidine monohydrate hydrochloride;Quinidine monohydrochloride monohydrate;6μ-Methoxycinchonan-9-ol hydrochloride monohydrate;QUINIDINE HYDROCHLORIDE ISO 9001:2015 REACH |
| CAS号 | 6151-40-2 |
| 分子式 | C20H27ClN2O3 |
| 分子量 | 378.9 |
| EINECS号 | 628-688-3 |
| 相关类别 | 小分子抑制剂;小分子抑制剂,天然产物;InhibitorsBuilding Blocks;QuinolinesCell Signaling Enzymes;Cell Signaling Enzymes;Heterocyclic Building Blocks;Substrates;Xenobiotics and Drug Metabolism;Xenobiotics and Drug Metabolism;and Substrates;Application Index;Biochemicals and Reagents;Building Blocks;C11 to C30;Cell Signaling Enzymes;Chemical Synthesis;Enzymes;Heterocyclic Building Blocks;Inhibitors;Quinolines |
| Mol文件 | 6151-40-2.mol |
| 结构式 | ![]() |
奎寧定鹽酸鹽 性质
| 熔点 | 258-259 C |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO:100mg/mL(263.93mM);水:2.5 mg/mL(6.60 mM) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| InChIKey | SGVZDMWHXVXUBY-KAIFKDDSSA-N |
| SMILES | O.Cl.[H][C@@]1(C[C@@H]2CC[N@H]1C[C@@H]2C=C)[C@@H](O)c3ccnc4ccc(OC)cc34 |
IC50: 19.9 μM (K + channel)
Quinidine hydrochloride monohydrate blocks WT mSlo3 (K Ca 5.1) channels with an IC 50 of 19.9±1.41 μM and Hill slope of 1.15±0.15 (n=7). Again, the potency of inhibition by Quinidine hydrochloride monohydrate is higher for F304Y mSlo3 (IC 50 of 2.42±0.60 μM, n=9, P<0.005; Hill slope of 0.98±0.12), but lower with R196Q mSlo3 (IC 50 of 38.4±6.77 μM, n=5, P<0.001; Hill slope of 1.05±0.16). The inhibition of F304Y mSlo3 by Quinidine hydrochloride monohydrate is observed to have some time dependence.
Direct application of Quinidine hydrochloride monohydrate on the sciatic nerve produces a dose-related decrease in amplitude at ascending somato-sensory evoked potential (SSEP) and descending compound muscle action potentials (CMAP) when comparing baseline with other time points, or when comparing the experimental left limb to the right contra-lateral glucose-treated limb. The latencies of SSEPs and CMAP potentials after Quinidine hydrochloride monohydrate applications are increased compare to baseline and the contralateral side.
安全信息
| 危险品标志 | Xn,Xi |
|---|---|
| 危险类别码 | 20/21/22-36/37/38 |
| 安全说明 | 36-26 |
| 危险品运输编号 | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 急性毒性 类别4 经皮 急性毒性 类别4 吸入 急性毒性 类别4 经口 |
